Compare Daito Pharmaceutical Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 37,441 Million (Small Cap)
20.00
NA
0.00%
0.11
5.85%
0.72
Revenue and Profits:
Net Sales:
11,591 Million
(Quarterly Results - Feb 2026)
Net Profit:
1,050 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.76%
0%
-9.76%
6 Months
-0.33%
0%
-0.33%
1 Year
-41.72%
0%
-41.72%
2 Years
-51.91%
0%
-51.91%
3 Years
-51.16%
0%
-51.16%
4 Years
-54.56%
0%
-54.56%
5 Years
-64.25%
0%
-64.25%
Daito Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.39%
EBIT Growth (5y)
-14.40%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.37
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.79
Tax Ratio
40.30%
Dividend Payout Ratio
55.80%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.93%
ROE (avg)
7.40%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
0.86
EV to EBIT
18.48
EV to EBITDA
7.19
EV to Capital Employed
0.88
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.75%
ROE (Latest)
4.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Feb'26 - YoY
Feb'26
Feb'25
Change(%)
Net Sales
11,591.00
12,025.00
-3.61%
Operating Profit (PBDIT) excl Other Income
2,269.00
1,502.00
51.07%
Interest
33.00
34.00
-2.94%
Exceptional Items
0.00
129.00
-100.00%
Consolidate Net Profit
1,050.00
372.00
182.26%
Operating Profit Margin (Excl OI)
97.10%
33.00%
6.41%
USD in Million.
Net Sales
YoY Growth in quarter ended Feb 2026 is -3.61% vs 13.96% in Feb 2025
Consolidated Net Profit
YoY Growth in quarter ended Feb 2026 is 182.26% vs -52.06% in Feb 2025
Annual Results Snapshot (Consolidated) - May'25
May'25
May'24
Change(%)
Net Sales
50,643.00
46,895.00
7.99%
Operating Profit (PBDIT) excl Other Income
6,953.00
7,553.00
-7.94%
Interest
123.00
41.00
200.00%
Exceptional Items
-33.00
45.00
-173.33%
Consolidate Net Profit
1,765.00
3,178.00
-44.46%
Operating Profit Margin (Excl OI)
51.80%
83.00%
-3.12%
USD in Million.
Net Sales
YoY Growth in year ended May 2025 is 7.99% vs 3.98% in May 2024
Consolidated Net Profit
YoY Growth in year ended May 2025 is -44.46% vs -9.90% in May 2024
About Daito Pharmaceutical Co., Ltd. 
Daito Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






